CAS: 950762-95-5; N-Hydroxy-1-(4-Methoxybenzyl)-1H-Indole-6-Carboxamide

上下游产品

PCI-34051 indole-6-carboxylic acid methyl ester p-Methoxybenzyl bromide

📜Methyl 1-(4-Methoxybenzyl)-1H-Indole-6-Carboxylate置于sodium Hydroxide,羟胺,盐酸体系中,用 四氢呋喃,甲醇,水 作为反应溶剂,化学反应 1.0H,以84%的收率获得产物pci 34051; N-羟基-1-(4-甲氧基苄基)-1H-吲哚-6-甲酰胺
参考文献: Indole Derivatives As Inhibitors Of Histone Deacetylase[fr] Dérivés D'Indole En Tant Qu'Inhibiteurs De L'Histone Désacétylase
标题: Indole Derivatives As Inhibitors Of Histone Deacetylase[fr] Dérivés D'Indole En Tant Qu'Inhibiteurs De L'Histone Désacétylase

专利信息

专利号:US-11285169-B2
优先权日:2013-03-13
标题 :Methods for modulating chemotherapeutic cytotoxicity
发明人：ROBERTS DAVID D; SOTO PANTOJA DAVID R
权利人:US HEALTH
摘要:Methods of reducing cytotoxicity of a chemotherapeutic agent to non-cancer cells by administering to a subject with cancer an effective amount of an agent that inhibits CD47 signaling and a DNA damaging agent, such as an anthracycline, topoisomerase inhibitor, or nucleotide synthesis inhibitor, are provided. Example disclosed methods reduce cardiotoxicity. In one example, the methods include administering to a subject with cancer an effective amount of a CD47 antisense morpholino oligonucleotide and an anthracycline such as doxorubicin. Methods of increasing cytotoxicity of a chemotherapeutic agent in cancer cells by administering to a subject with a tumor an effective amount of an agent that inhibits CD47 signaling and a DNA damaging agent such as an anthracycline, topoisomerase inhibitor, or nucleotide synthesis inhibitor, are also provided. In some embodiments, the inhibitor of CD47 signaling is administered to the subject before, during, or after the administration of the DNA damaging agent.

专利号:US-11801251-B2
优先权日:2015-11-03
标 题 :Selective HDAC8 inhibitors and their uses
发明人：MEYER-ALMES FRANZ-JOSEF; MEYNERS CHRISTIAN; KLEINSCHEK ALEXANDER; HAUS PATRICIA
权利人:HOCHSCHULE DARMSTADT
摘要:The present invention relates to small molecule compounds based on benzopyrimido- or benzoimidazo-thiazin-imine as well as their (synthesis) intermediates and their use as HDAC inhibitors, in particular HDAC8 inhibitors. The present invention also relates to the use of said compounds in the treatment of cancer and as therapeutic agents for eukaryotic parasites and respective methods of treatment.